Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRK-950 in advanced solid tumors
NCT02990481Phase 1Completed
- Sponsor
- Toray Industries
- Start
- Mar 2017
- Primary completion
- Sep 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of TRK-950 in solid tumor, colon cancer and cholangiocarcinoma (CCA) (3 arms), sponsored by Toray Industries. Primary endpoints: Adverse event at 1 year, CTCAE version 4.03 at 1 year and 9 more. Started Mar 2017; status: completed.
02
Drugs
TRK-950
03
Conditions
solid tumorcolon cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02990481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02990481.